A Retrospective Observational Study on COVID-19 Patients Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID)

DOI record: { "DOI": "10.1007/s41030-025-00316-z", "ISSN": [ "2364-1754", "2364-1746" ], "URL": "http://dx.doi.org/10.1007/s41030-025-00316-z", "alternative-id": [ "316" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "27 July 2025" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "2 September 2025" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "6 October 2025" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of Interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "Mariam M. Murad, Stephen L. Atkin, Pearl W. Wasif, Alwaleed Abdulaziz Behzad, Aamal M. J. Abdulla Husain, Florence Lefebvre d’Hellencourt, Jean Joury, Mohamed Abdel Aziz, Hammam Haridy, Julia Spinardi, Lu Wang, Fiona Boland, Moe H. Kyaw, and Manaf Al-Qahtani have nothing to disclose." }, { "group": { "label": "Ethics approval", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "The study was conducted according to the guidelines and approved by the National COVID-19 Taskforce ethical approval, obtained in June 2023 for this retrospective study (CRT-COVID2022-160). A waiver which aligns with FDA guidelines that permits us to use the participants’ information for this study, including for publication purposes, was obtained from the National COVID-19 Taskforce ethics committee, allowing us to proceed without additional consent." } ], "author": [ { "ORCID": "https://orcid.org/0009-0008-8006-996X", "affiliation": [], "authenticated-orcid": false, "family": "Murad", "given": "Mariam M.", "sequence": "first" }, { "affiliation": [], "family": "Atkin", "given": "Stephen L.", "sequence": "additional" }, { "affiliation": [], "family": "Wasif", "given": "Pearl W.", "sequence": "additional" }, { "affiliation": [], "family": "Behzad", "given": "Alwaleed Abdulaziz", "sequence": "additional" }, { "affiliation": [], "family": "Husain", "given": "Aamal M. J. Abdulla", "sequence": "additional" }, { "affiliation": [], "family": "d’Hellencourt", "given": "Florence Lefebvre", "sequence": "additional" }, { "affiliation": [], "family": "Joury", "given": "Jean", "sequence": "additional" }, { "affiliation": [], "family": "Aziz", "given": "Mohamed Abdel", "sequence": "additional" }, { "affiliation": [], "family": "Haridy", "given": "Hammam", "sequence": "additional" }, { "affiliation": [], "family": "Spinardi", "given": "Julia", "sequence": "additional" }, { "affiliation": [], "family": "Wang", "given": "Lu", "sequence": "additional" }, { "affiliation": [], "family": "Boland", "given": "Fiona", "sequence": "additional" }, { "affiliation": [], "family": "Kyaw", "given": "Moe H.", "sequence": "additional" }, { "affiliation": [], "family": "Al-Qahtani", "given": "Manaf", "sequence": "additional" } ], "container-title": "Pulmonary Therapy", "container-title-short": "Pulm Ther", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2025, 10, 6 ] ], "date-time": "2025-10-06T14:10:05Z", "timestamp": 1759759805000 }, "deposited": { "date-parts": [ [ 2025, 10, 6 ] ], "date-time": "2025-10-06T14:10:10Z", "timestamp": 1759759810000 }, "funder": [ { "DOI": "10.13039/100004319", "award": [ "76181715" ], "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/100004319", "id-type": "DOI" } ], "name": "Pfizer" } ], "indexed": { "date-parts": [ [ 2025, 10, 6 ] ], "date-time": "2025-10-06T14:43:59Z", "timestamp": 1759761839613, "version": "build-2065373602" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2025, 10, 6 ] ] }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 10, 6 ] ], "date-time": "2025-10-06T00:00:00Z", "timestamp": 1759708800000 } }, { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 10, 6 ] ], "date-time": "2025-10-06T00:00:00Z", "timestamp": 1759708800000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s41030-025-00316-z.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s41030-025-00316-z/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s41030-025-00316-z.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1007", "published": { "date-parts": [ [ 2025, 10, 6 ] ] }, "published-online": { "date-parts": [ [ 2025, 10, 6 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "316_CR1", "unstructured": ": World Health Organization; 2020 [Available from: https://www.euro.who.int/en/healthtopics/health-emergencies/coronavirus-covid19/news/news/2020/01/2019-ncovoutbreak-is-an-emergency-of-international-concern." }, { "key": "316_CR2", "unstructured": "WHO Situation Report 51 Coronavirus disease 2019 (COVID-19) : World Health Organization; 2019 [Available from: https://www.euro.who.int/en/healthtopics/health-emergencies/coronavirus-covid19/news/news/2020/01/2019-ncovoutbreak-is-an-emergency-of-international-concern." }, { "DOI": "10.1016/j.ijid.2020.10.091", "author": "M Al-Qahtani", "doi-asserted-by": "publisher", "first-page": "285", "journal-title": "Int J Infect Dis", "key": "316_CR3", "unstructured": "Al-Qahtani M, AlAli S, AbdulRahman A, Salman Alsayyad A, Otoom S, Atkin SL. The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects. Int J Infect Dis. 2021;102:285–8.", "volume": "102", "year": "2021" }, { "DOI": "10.1136/bmj.m1985", "author": "AB Docherty", "doi-asserted-by": "publisher", "journal-title": "BMJ", "key": "316_CR4", "unstructured": "Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.", "volume": "369", "year": "2020" }, { "key": "316_CR5", "unstructured": "Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet. 2022;399 (10334):1513–36." }, { "key": "316_CR6", "unstructured": "CDC. Estimated disease burden of COVID-19. Centers for disease control and prevention. Data and Surveillance Web site: Centers for Disease Control and Prevention.; 2020 [updated october 2 2021]. Available from: Web site. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden." }, { "key": "316_CR7", "unstructured": "NIH. COVID-19 Treatment Guidelines National Institutes of Health; 2021 [updated December 16 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/outpatient-management." }, { "key": "316_CR8", "unstructured": "NIH. The COVID-19 Treatment Guideline Panel’s Statement on Therapies for High-Risk, Nonhospitalized Patients with Mild to Moderate COVID-19: National Institute of Health; 2021 [updated Updated December 30, 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients." }, { "DOI": "10.15585/mmwr.mm7148e2", "author": "MM Shah", "doi-asserted-by": "publisher", "first-page": "1531", "issue": "48", "journal-title": "MMWR Morb Mortal Wkly Rep", "key": "316_CR9", "unstructured": "Shah MM, Joyce B, Plumb ID, Sahakian S, Feldstein LR, Barkley E, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19 — United States, April–September 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1531–7.", "volume": "71", "year": "2022" }, { "DOI": "10.1155/2022/7341493", "author": "M Marzi", "doi-asserted-by": "publisher", "first-page": "1", "journal-title": "Biomed Res Int", "key": "316_CR10", "unstructured": "Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E. Paxlovid: mechanism of action, synthesis, and in silico study. Biomed Res Int. 2022;2022:1–16.", "volume": "2022", "year": "2022" }, { "DOI": "10.1056/NEJMoa2107934", "author": "A Gupta", "doi-asserted-by": "publisher", "first-page": "1941", "issue": "21", "journal-title": "N Engl J Med", "key": "316_CR11", "unstructured": "Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–50.", "volume": "385", "year": "2021" }, { "DOI": "10.1056/NEJMoa2116044", "doi-asserted-by": "crossref", "key": "316_CR12", "unstructured": "Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. New Engl J Med. 2022;386 (6):509–20." }, { "DOI": "10.1016/j.antiviral.2022.105252", "author": "L Vangeel", "doi-asserted-by": "publisher", "journal-title": "Antivir Res", "key": "316_CR13", "unstructured": "Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antivir Res. 2022;198:105252.", "volume": "198", "year": "2022" }, { "DOI": "10.1371/journal.pone.0284006", "author": "KM Souza", "doi-asserted-by": "publisher", "issue": "10", "journal-title": "PLoS One", "key": "316_CR14", "unstructured": "Souza KM, Carrasco G, Rojas-Cortés R, Michel Barbosa M, Bambirra EHF, Castro JL, et al. Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: systematic review and meta-analyses of observational studies. PLoS One. 2023;18(10):e0284006.", "volume": "18", "year": "2023" }, { "DOI": "10.1097/MJT.0000000000001744", "author": "AS Cha-Silva", "doi-asserted-by": "publisher", "first-page": "e246", "issue": "3", "journal-title": "Am J Ther", "key": "316_CR15", "unstructured": "Cha-Silva AS, Gavaghan MB, Bergroth T, Alexander-Parrish R, Yang J, Draica F, et al. Effectiveness of nirmatrelvir-ritonavir for the prevention of COVID-19-related hospitalization and mortality: a systematic literature review. Am J Ther. 2024;31(3):e246–57.", "volume": "31", "year": "2024" }, { "DOI": "10.1136/bmj.m1966", "author": "CM Petrilli", "doi-asserted-by": "publisher", "journal-title": "BMJ", "key": "316_CR16", "unstructured": "Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.", "volume": "369", "year": "2020" }, { "DOI": "10.1001/jamanetworkopen.2021.0417", "author": "NT Nguyen", "doi-asserted-by": "publisher", "issue": "3", "journal-title": "JAMA Netw Open", "key": "316_CR17", "unstructured": "Nguyen NT, Chinn J, Nahmias J, Yuen S, Kirby KA, Hohmann S, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open. 2021;4(3):e210417.", "volume": "4", "year": "2021" }, { "DOI": "10.1038/s41598-022-26042-z", "author": "A Al Mutair", "doi-asserted-by": "publisher", "first-page": "21487", "issue": "1", "journal-title": "Sci Rep", "key": "316_CR18", "unstructured": "Al Mutair A, Layqah L, Alhassan B, Alkhalifah S, Almossabeh M, AlSaleh T, et al. Estimated cost of treating hospitalized COVID-19 patients in Saudi Arabia. Sci Rep. 2022;12(1):21487.", "volume": "12", "year": "2022" }, { "DOI": "10.1093/cid/ciac443", "author": "R Najjar-Debbiny", "doi-asserted-by": "publisher", "first-page": "e342", "issue": "3", "journal-title": "Clin Infect Dis", "key": "316_CR19", "unstructured": "Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342–9.", "volume": "76", "year": "2023" }, { "DOI": "10.5334/gh.814", "author": "K Matsushita", "doi-asserted-by": "publisher", "first-page": "64", "issue": "1", "journal-title": "Glob Heart", "key": "316_CR20", "unstructured": "Matsushita K, Ding N, Kou M, Hu X, Chen M, Gao Y, et al. The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: a systematic review and meta-analysis. Glob Heart. 2020;15(1):64.", "volume": "15", "year": "2020" }, { "key": "316_CR21", "unstructured": "Site: CfDCaPDSW. Underlying conditions and the higher risk for severe COVID-19: Centers for Disease Control and Prevention; 2024. [Available from: https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html." }, { "DOI": "10.15585/mmwr.mm7148e2", "author": "MM Shah", "doi-asserted-by": "publisher", "first-page": "1531", "issue": "48", "journal-title": "MMWR Morb Mortal Wkly Rep", "key": "316_CR22", "unstructured": "Shah MM, Joyce B, Plumb ID, Sahakian S, Feldstein LR, Barkley E, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19 - United States, April-September 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1531–7.", "volume": "71", "year": "2022" }, { "DOI": "10.1016/S1473-3099(24)00353-0", "author": "MH Choi", "doi-asserted-by": "publisher", "first-page": "1213", "issue": "11", "journal-title": "Lancet Infect Dis", "key": "316_CR23", "unstructured": "Choi MH, Wan EYF, Wong ICK, Chan EWY, Chu WM, Tam AR, et al. Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir-ritonavir in patients hospitalised with COVID-19: a target trial emulation study. Lancet Infect Dis. 2024;24(11):1213–24.", "volume": "24", "year": "2024" }, { "DOI": "10.7189/jogh.12.05014", "author": "Q Healey", "doi-asserted-by": "publisher", "first-page": "05014", "journal-title": "J Glob Health", "key": "316_CR24", "unstructured": "Healey Q, Sheikh A, Daines L, Vasileiou E. Symptoms and signs of long COVID: a rapid review and meta-analysis. J Glob Health. 2022;12:05014.", "volume": "12", "year": "2022" }, { "DOI": "10.1056/NEJMoa2118542", "author": "J Hammond", "doi-asserted-by": "publisher", "first-page": "1397", "issue": "15", "journal-title": "N Engl J Med", "key": "316_CR25", "unstructured": "Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–408.", "volume": "386", "year": "2022" }, { "DOI": "10.7759/cureus.36528", "author": "SMH Zaidi", "doi-asserted-by": "publisher", "journal-title": "Cureus", "key": "316_CR26", "unstructured": "Zaidi SMH, Iskander PA, Ahmed K, Jaber F, Paz M, Khan A, et al. A rare case of Paxlovid-induced pancreatitis. Cureus. 2023. https://doi.org/10.7759/cureus.36528.", "year": "2023" }, { "DOI": "10.1016/j.antiviral.2023.105659", "author": "H Cai", "doi-asserted-by": "publisher", "journal-title": "Antiviral Res", "key": "316_CR27", "unstructured": "Cai H, Yan J, Liu S, Li P, Ding L, Zhan Y, et al. Paxlovid for hospitalized COVID-19 patients with chronic kidney disease. Antiviral Res. 2023;216:105659.", "volume": "216", "year": "2023" }, { "DOI": "10.1038/s41586-022-05514-2", "author": "S Iketani", "doi-asserted-by": "publisher", "first-page": "558", "issue": "7944", "journal-title": "Nature", "key": "316_CR28", "unstructured": "Iketani S, Mohri H, Culbertson B, Hong SJ, Duan Y, Luck MI, et al. Multiple pathways for SARS-CoV-2 resistance to Nirmatrelvir. Nature. 2022;613(7944):558–64.", "volume": "613", "year": "2022" }, { "DOI": "10.1101/2022.06.21.22276724", "doi-asserted-by": "crossref", "key": "316_CR29", "unstructured": "Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv: the preprint server for health sciences. 2022." }, { "DOI": "10.3389/fpubh.2023.1174879", "author": "W Zhang", "doi-asserted-by": "publisher", "journal-title": "Front Public Health", "key": "316_CR30", "unstructured": "Zhang W, Li L, Zhou Z, Liu Q, Wang G, Liu D. Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China. Front Public Health. 2023. https://doi.org/10.3389/fpubh.2023.1174879.", "year": "2023" }, { "DOI": "10.1002/rmv.2476", "author": "C Zhu", "doi-asserted-by": "publisher", "journal-title": "Rev Med Virol", "key": "316_CR31", "unstructured": "Zhu C, Yin J, Chen X, Liu M, Yang S. Appraisal of evidence reliability and applicability of Paxlovid as treatment for SARS-COV-2 infection: a systematic review. Rev Med Virol. 2023. https://doi.org/10.1002/rmv.2476.", "year": "2023" }, { "DOI": "10.1371/journal.pone.0270300", "author": "KM Al-Shami", "doi-asserted-by": "publisher", "issue": "6", "journal-title": "PLoS One", "key": "316_CR32", "unstructured": "Al-Shami KM, Ahmed WS, Alzoubi KH. Motivators and barriers towards clinical research participation: a population-based survey from an Arab MENA country. PLoS One. 2022;17(6):e0270300.", "volume": "17", "year": "2022" } ], "reference-count": 32, "references-count": 32, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s41030-025-00316-z" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "A Retrospective Observational Study on COVID-19 Patients Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID)", "type": "journal-article", "update-policy": "https://doi.org/10.1007/springer_crossmark_policy" }